How we track ALS progression and why does it matter? @EverythingALS
How we track ALS progression and why does it matter?  @EverythingALS
Uploaded July 2022 | Updated September 2026, 2 weeks ago
Christina Fournier
MD
Associate Professor at Emory University

Dr. Christina Fournier is an Associate Professor of Neurology at Emory University. She is the director of the Atlanta VA ALS Clinic, co-director of the Emory ALS Center, and Emory Neuromuscular Division director. Her clinical work is focused on the care of patients with ALS and neuromuscular disorders, and her research interests include improving outcome measures and research methods for ALS clinical studies. She serves as site investigator for numerous multicenter ALS clinical trials and non-interventional ALS research studies
How we track ALS progression and why does it matter?Clinical trial opens enrollment: shifting the PARADIGM with PrimeC by Alon Ben-NoonDeveloping a Robust Diagnostic Test for ALS by Dr. Sandra Banack from Brain Chemistry Labs.Genetics and ALS: What New Discoveries Mean for You and Your Family with Jennifer Roggenbuck MS, CGCTPN-101 Clinical Trial: for ALS & the C9orf72 Mutation - an Overview of the Trial plus Q&AGene & Cell Therapy ALS Trial: Transplanting stem cells into the motor cortex of patients with ALSFast-Tracking Discovery in ALS:Collaboration, Innovation, and Open ScienceStories and Innovation in ALS Episode# 9:  A Tale of an ALS Reversal with McFinn LovereDr. Ostrow discusses precision medicine in ALS2024 ALS Reversals Update by Dr. Richard Bedlack M.D., Ph.D2022 Outlook for ALSHarnessing The Power of Citizen Research By Mcfinn Lovere, Dave Shulman Michael Thayer Janie Gobeli
Everything ALS |

How we track ALS progression and why does it matter?

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER